BioPharmSignal logoBioPharmSignal

Biotech News

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

Rhythm Pharmaceuticals (RYTM)Rhythm PharmaceuticalsPartnership

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 --

-- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --

Related news

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

RYTMRhythm Pharmaceuticals2026-09-22 12:00 EST

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

ALGSAligos Therapeutics2026-07-06 20:05 EST

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

SENSSenseonics2026-09-14 11:00 EST

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

LXRXLexicon Pharmaceuticals2026-10-21 12:30 EST

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

View all latest news

Rhythm Pharmaceuticals

Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations. IMCIVREE...

Recent company news

RYTMRhythm Pharmaceuticals2026-11-04 13:00 EST

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

RYTMRhythm Pharmaceuticals2026-11-03 02:59 EST

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Stock data

Close
105.02 USD
Market cap
5.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States